Literature DB >> 3476492

Cross susceptibility and absence of cross resistance to cefotetan and cefoxitin.

A L Barry, R N Jones.   

Abstract

Tests with 2,713 bacterial isolates (members of the family Enterobacteriaceae and gram-positive cocci) from 14 laboratories compared cefoxitin MICs with cefotetan MICs. Strains that were susceptible to cefoxitin could be assumed to be susceptible to cefotetan. Over half of the cefoxitin-resistant isolates of the Enterobacteriaceae were susceptible to cefotetan.

Entities:  

Mesh：

Substances：

Year:  1987        PMID： 3476492      PMCID： PMC269276          DOI： 10.1128/jcm.25.8.1570-1571.1987

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN： 0095-1137            Impact factor:   5.948


  4 in total

1.  Antimicrobial activity of cefmetazole (CS-1170) and recommendations for susceptibility testing by disk diffusion, dilution, and anaerobic methods.

Authors:  R N Jones; A L Barry; P C Fuchs; C Thornsberry
Journal:  J Clin Microbiol       Date:  1986-12       Impact factor: 5.948

2.  Antimicrobial activity, beta-lactamase stability and beta-lactamase inhibition of cefotetan and other 7-alpha-methoxy beta-lactam antimicrobials.

Authors:  R N Jones; H W Wilson
Journal:  Diagn Microbiol Infect Dis       Date:  1983-03       Impact factor: 2.803

3.  Cefotetan, a new cephamycin: comparison of in vitro antimicrobial activity with other cephems, beta-lactamase stability, and preliminary recommendations for disk diffusion testing.

Authors:  L W Ayers; R N Jones; A L Barry; C Thornsberry; P C Fuchs; T L Gavan; E H Gerlach; H M Sommers
Journal:  Antimicrob Agents Chemother       Date:  1982-11       Impact factor: 5.191

4.  Cefotetan pharmacokinetics in volunteers with various degrees of renal function.

Authors:  B R Smith; J L LeFrock; P T Thyrum; B A Doret; C Yeh; G Onesti; A Schwartz; J J Zimmerman
Journal:  Antimicrob Agents Chemother       Date:  1986-05       Impact factor: 5.191
  4 in total
  4 in total

1.  Use of in vitro vancomycin testing results to predict susceptibility to oritavancin, a new long-acting lipoglycopeptide.

Authors:  Ronald N Jones; John D Turnidge; Greg Moeck; Francis F Arhin; Rodrigo E Mendes
Journal:  Antimicrob Agents Chemother       Date:  2015-02-09       Impact factor: 5.191

2.  Cross-resistance and cross-susceptibility between fluoroquinolone agents.

Authors:  A L Barry; P C Fuchs
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1991-12       Impact factor: 3.267

3.  Selection of a surrogate agent (vancomycin or teicoplanin) for initial susceptibility testing of dalbavancin: results from an international antimicrobial surveillance program.

Authors:  Ronald N Jones; Helio S Sader; Thomas R Fritsche; Patricia A Hogan; Daniel J Sheehan
Journal:  J Clin Microbiol       Date:  2006-07       Impact factor: 5.948

4.  Cefotetan: a second-generation cephalosporin active against anaerobic bacteria. Committee on Antimicrobial Agents, Canadian Infectious Disease Society.

Authors:  M J Gribble
Journal:  CMAJ       Date:  1994-09-01       Impact factor: 8.262
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.